https://www.selleckchem.com/pr....oducts/nesuparib.htm
Assuming a prior 4.3% risk of RM, the true rate of RM for SC Dmax of ≤14Gy was computed as 1% with 98% probability. In one of the largest series of patients treated with single fraction, de novo SSRS, there were no cases of RM observed with a median follow-up of 42months. These data support safe relaxation of MRI-defined SC dose up to D0.01cc≤12Gy, which corresponds to 1% risk of RM. In one of the largest series of patients treated with single fraction, de novo SSRS, there were no cases of RM observed with a median follow-up o
Like
Comment
Share
